Chinese biopharmaceutical company Kexing Biopharm Co Ltd (SHA:688136) announced on Thursday that the first subject has been enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently developed by its subsidiary Shenzhen Kexing Pharmaceutical Co Ltd.

Designed to treat neovascular age-related macular degeneration (nAMD), GB10 is a high-concentration, ophthalmic protein drug formulation that features a bispecific antibody targeting both VEGF and Ang-2. The company says that with a high concentration of 140 mg/mL, GB10 Injection allows for a smaller injection volume or higher dosage, thereby extending the dosing interval. It is expected to achieve a 'once per four months' dosing schedule, significantly improving patient compliance.

Preclinical data indicate international competitiveness of GB10 Injection in terms of both biological activity and in vivo efficacy. In a laser-induced choroidal neovascularisation (CNV) monkey model, it demonstrated effective inhibition of pathological ocular neovascularisation in the fundus.

nAMD remains a leading cause of blindness globally among individuals aged over 50.